DESTINY-Breast04 'Practice Changing' for HER2-Low Breast Cancer

(MedPage Today) -- Trastuzumab deruxtecan (Enhertu) demonstrated a statistically significant benefit in progression-free survival in patients with HER2-low metastatic breast cancer, meeting the primary endpoint of the phase III DESTINY-Breast04...